Drug Trial Radar · NCT06008119
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
165
Planned (sponsor's estimate)
Start
Oct 25, 2023
Primary completion
Dec 24, 2026
Study completion Dec 24, 2026
Sponsor
- Lead sponsor
- Shanghai Kechow Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, Phase 3 study
Conditions
- Colorectal Cancer Metastatic
Interventions
Tunlametinib plus VemurafenibDrug
12mg BID Tunlametinib+720mg BID Vemurafenib
Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± CetuximabDrug
According to investigators' suggestion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Oncology Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.